ADESÃO AO TRATAMENTO FARMACOLÓGICO POR PACIENTES PORTADORES DE ESCLEROSE MÚLTIPLA

Abstract

Multiple sclerosis is a chronic, progressive autoimmune disease characterized by neurodegeneration and demyelination, which can affect the white and gray matter of the central nervous system. Although considered one of the non-traumatic neurological conditions that cause disability in young adults, there is still no curative therapy, the available drug treatments seek to reduce inflammatory activity and slow down the progression of the disease. Currently in Brazil there are several medicines made available by the Unified Health System through the Specialized Component of Pharmaceutical Assistance for multiple sclerosis. In this sense, this study aimed to evaluate patients adherence to the prescribed pharmacological treatment. A retrospective, descriptive and quantitative study was carried out with analysis of data from patients diagnosed with multiple sclerosis registered at Specialized Component of Pharmaceutical Assistance in the State of Mato Grosso do Sul. Data were collected through the Computerized System for Management and Monitoring of Exceptional Medications. Adherence was obtained indirectly by checking the medication possession ratio (MPR). Thus, data were collected from 158 individuals, of which 77.2% were female, 69% were aged between 30 and 59 years, 40.5% were eutrophic, 12.7% had systemic arterial hypertension. and 1.9% diabetes, as for smoking, a prevalence of 5.7% was found. Furthermore, 62.7% had previously undergone some treatment for multiple sclerosis and the most used medication was fingolimod (38%). The total mean medication possession rate was higher for treatment with beta interferon 30 µg (99%) and adherence to pharmacological treatment for multiple sclerosis was higher in the group of patients treated with glatiramer acetate 40 mg with (92.6%). Regarding gender, it was observed that females showed greater adherence to most medications.